Fred R. Hirsch, MD, PhD

Articles

Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLC

August 12th 2024

Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.

Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC

July 25th 2024

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

Dr. Hirsch on Diagnosing and Managing Metastatic SCLC

January 16th 2023

Fred R. Hirsch, MD, PhD, discusses the rarity of diagnosing small cell lung cancer early in the disease course, unmet needs in SCLC screening, the importance of ECOG performance score when considering patients for clinical trials, and factors influencing hospice care decisions in patients with SCLC.

Dr. Hirsch on the Expansion of Molecular Testing in Lung Cancer

November 12th 2019

Fred R. Hirsch, MD, PhD, discusses the expansion of molecular testing in lung cancer.

Dr. Hirsch on Value of PD-L1 Testing in Patients With Lung Cancer

September 23rd 2016

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer (IASLC), discusses the value of PD-L1 assays for patients with non–small cell lung cancer. Hirsch shared his during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. Hirsch on Importance of Molecular Testing in Lung Cancer

August 5th 2016

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer, discusses the importance of molecular testing for patients with lung cancer.

Dr. Fred Hirsch on Next Steps for Necitumumab in NSCLC

April 19th 2016

Fred R. Hirsch, MD, PhD, professor of medicine and pathology, University of Colorado Cancer Center, CEO, International Association for the Study of Lung Cancer (IASLC), discusses necitumumab for first-line treatment of advanced squamous non-small cell lung cancer (NSCLC).

Dr. Hirsch Discusses the Role of Next-Generation EGFR Inhibitors

August 1st 2014

Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the role of next-generation EGFR inhibitors.